XML 47 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Acquisitions - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Feb. 28, 2019
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Business Acquisition [Line Items]        
Goodwill   $ 140,627,000   $ 140,627,000
Estimated fair value of contingent consideration, long-term liabilities   110,832,000   108,968,000
Change in the estimated fair value of contingent consideration   1,864,000 $ 5,384,000  
Cobalt Biomedicine, Inc | Acquisition Agreement        
Business Acquisition [Line Items]        
Business acquisition, percentage of voting interests acquired 100.00%      
Business acquisition, impairment of intangible assets or goodwill $ 0      
Goodwill 140,600,000      
Maximum contingent consideration upon achievement of certain pre-specified development milestones $ 500,000,000.0      
Maximum term for success payment 20 years      
Cobalt Biomedicine, Inc | Acquisition Agreement | Research and Development Expense        
Business Acquisition [Line Items]        
Change in estimated fair value of success payment   100,000 27,900,000  
Change in the estimated fair value of contingent consideration   1,900,000 $ 5,400,000  
Cobalt Biomedicine, Inc | Acquisition Agreement | Long-term Liabilities        
Business Acquisition [Line Items]        
Estimated fair value of success payment liability   4,300,000   4,200,000
Estimated fair value of contingent consideration   $ 110,800,000   $ 109,000,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Minimum        
Business Acquisition [Line Items]        
Threshold market capitalization $ 8,100,000,000      
Cobalt Biomedicine, Inc | Acquisition Agreement | Market Capitalization Equal to or Exceeds $8.1 billion        
Business Acquisition [Line Items]        
Cobalt success payment 500,000,000.0      
Cobalt Biomedicine, Inc | Acquisition Agreement | IPR&D        
Business Acquisition [Line Items]        
Business combination, intangible assets $ 59,200,000